Anti-nociceptive efficacy of the soluble epoxide hydrolase inhibitor t-TUCB in horses with mechanically induced lameness.

This study evaluated the pain-relieving effectiveness of a drug called t-TUCB, an inhibitor of soluble epoxide hydrolase (sEH), in horses that had lameness induced mechanically. The findings suggest that t-TUCB potentially offers significant analgesic benefits for horses.

Introduction

In the context of pain management in horses, anti-inflammatory and analgesic agents are vital. This research interrogates a potential novel solution, focusing on inhibitors of soluble epoxide hydrolase (sEH), a class of drugs increasingly being recognized for their anti-inflammatory and analgesic properties. Specifically, this study investigated the effect of trans-4-{4-[3-(4-trifluro-methoxy-phenyl)-ureido]-cyclohexyloxy}-benzoic acid (t-TUCB), an sEH inhibitor.

Methodology

The methodology involved several defined steps:

• An adjustable heart bar shoe (a-HBS) model was used to induce lameness meaningfully and reversibly — ensuring that the lameness could be removed post-study — in eight horses across a 24-hour period.
• At the outset (time 0), a baseline level of lameness was evaluated.
• Both a control placebo (DMSO) and t-TUCB were administered intravenously. The dosage of t-TUCB was fixed at 1 mg/kg.
• Subsequent to administration, researchers measured lameness using an inertial sensor system. This assessment was performed across six defined time-points: at zero, one, three, six, twelve, and twenty-four hours.
• To facilitate subjective evaluation, front-facing videos were captured coinciding with the six time-points employing a visual analog scale (VAS). These were subsequently assessed by three different evaluators, blind to the purpose of the trial.

Results

The results of the study confirmed the researchers’ hypothesis:

• Within one hour of t-TUCB administration, there was a significant improvement in lameness as compared to the placebo. This improvement was even more marked when compared against baseline lameness and continued to be observed at three and six hours post-administration.
• In contrast, there was a worsening of lameness twelve hours after the placebo administration as compared to the baseline.
• Within 24 hours following the conclusion of the induced lameness testing, all horses returned to their baseline soundness levels.

Conclusions

The results of this study showed the potential of t-TUCB to alleviate pain in horses. The single-dose intravenous administration of t-TUCB was effective in inducing notable improvements in mechanically induced lameness. These findings suggest that the sEH inhibitor t-TUCB could be a novel and promising analgesic for horses.